May 8 |
Revolution Medicines GAAP EPS of -$0.70 beats by $0.05
|
May 8 |
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
|
May 7 |
Revolution Medicines Q1 2024 Earnings Preview
|
May 4 |
Insider Sale: CFO Jack Anders Sells 10,000 Shares of Revolution Medicines Inc (RVMD)
|
May 1 |
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
|
Apr 12 |
Top 3 Health Care Stocks That May Collapse In Q2
|
Apr 12 |
Revolution Medicines: An Expensive Shot At A Massive Market Opportunity
|
Apr 10 |
Roblox, TAL Education And Other Big Stocks Moving Higher On Wednesday
|
Apr 9 |
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
|
Apr 8 |
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
|